Allogene Therapeutics (NASDAQ:ALLO) Receives “Buy” Rating from HC Wainwright
HC Wainwright reissued their buy rating on shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) in a report published on Thursday, Benzinga reports. HC Wainwright currently has a $9.00 price target on the stock. Other equities analysts also recently issued research reports about the stock. Piper Sandler initiated coverage on shares of Allogene Therapeutics in […]
More Stories
Intellectus Partners LLC Grows Position in Archer Aviation Inc. (NYSE:ACHR)
Intellectus Partners LLC grew its position in shares of Archer Aviation Inc. (NYSE:ACHR – Free Report) by 1.3% during the...
Balboa Wealth Partners Has $686,000 Stock Position in iShares Russell 2000 ETF (NYSEARCA:IWM)
Balboa Wealth Partners decreased its holdings in iShares Russell 2000 ETF (NYSEARCA:IWM – Free Report) by 13.0% during the 3rd...
Invesco S&P 500 High Dividend Low Volatility ETF (NYSEARCA:SPHD) Shares Sold by Lifeworks Advisors LLC
Lifeworks Advisors LLC trimmed its stake in shares of Invesco S&P 500 High Dividend Low Volatility ETF (NYSEARCA:SPHD – Free...
Balboa Wealth Partners Sells 2,033 Shares of SPDR S&P MidCap 400 ETF Trust (NYSEARCA:MDY)
Balboa Wealth Partners reduced its stake in SPDR S&P MidCap 400 ETF Trust (NYSEARCA:MDY – Free Report) by 18.2% in...
Balboa Wealth Partners Sells 950 Shares of AerCap Holdings (NYSE:AER)
Balboa Wealth Partners decreased its position in AerCap Holdings (NYSE:AER – Free Report) by 7.0% during the 3rd quarter, according...
Hillenbrand (NYSE:HI) Releases FY 2025 Earnings Guidance
Hillenbrand (NYSE:HI – Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share...